Amarin (AMRN) Dips as Another Group DOESN'T Expect NCE
Tweet
Share
E-mail
Get Alerts AMRN Hot Sheet
Price: $14.88 -1.59%
Rating Summary:
6 Buy, 12 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 11 | New: 17
Rating Summary:
6 Buy, 12 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 11 | New: 17
Join SI Premium – FREE
Amarin Corporation plc (NASDAQ: AMRN) dipped lower mid-day Thursday following a note from research firm Marwood Group that they don't expect NCE designation for the company's Vascepa.
According to a tweet from noted biotech watcher Adam Feuerstein of TheStreet.com:
@adamfeuerstein
Marwood Group Research report issued today predicting NO Vacepa NCE.
Shares of AMRN last traded at $12.40, down 0.2%
According to a tweet from noted biotech watcher Adam Feuerstein of TheStreet.com:
@adamfeuerstein
Marwood Group Research report issued today predicting NO Vacepa NCE.
Shares of AMRN last traded at $12.40, down 0.2%
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Macquarie Double Upgrades Kinsus Interconnect Technology Corp (3189:TT) to Outperform
- Nurix (NRIX) PT Raised to $34 at Mizuho
- Bitdeer breaks ground on $36M Nevada manufacturing facility
Create E-mail Alert Related Categories
Analyst Comments, Trader TalkRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
